New combo aims to slow lung scarring in IPF patients
NCT ID NCT07583589
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding dextromethorphan to the standard drug nidanib helps people with idiopathic pulmonary fibrosis (IPF). About 60 adults aged 40 and older will take either the combo or nidanib alone for 12 weeks. The main goal is to see if lung function (FVC) improves or declines less, with cough and side effects also tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nidanib and dextromethorphan
- What this could lead to
- If it works, this could point toward a better treatment for IPF that slows lung decline and reduces coughing.
- What could go wrong
- This is a small, early-phase trial with only 60 people. The combination may not work better than nidanib alone, and side effects like stomach issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays
- Inhaled drug could offer new hope for lung scarring disease
- New hope for lung scarring: AZD8965 enters Mid-Stage trial